Metraipolis › archive › dc_e88cb1325df0

Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies — Europe PMC PMID:41114975

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41114975
DOI
10.1001/jamanetworkopen.2025.38277
License (as archived)
solo-consultazione
Archived
2026-11-09T15:52:29.790Z
SHA-256 of the archived text
daad0303a1cf3166b6d41fc61016d1876a5e7857dd393c18db1d530e9d590388
Stable URL of this page
https://metraipolis.com/documento/dc_e88cb1325df0

How to cite

Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies — Europe PMC PMID:41114975 — Europe PMC (en), https://europepmc.org/article/MED/41114975 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e88cb1325df0 (Metraipolis archive dc_e88cb1325df0, sha256 daad0303a1cf3166b6d41fc61016d1876a5e7857dd393c18db1d530e9d590388)
BibTeX
@misc{dce88cb1325df0,
  title = {Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies — Europe PMC PMID:41114975},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41114975},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e88cb1325df0; sha256 daad0303a1cf3166b6d41fc61016d1876a5e7857dd393c18db1d530e9d590388},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41114975. Agents can read the archived copy with the MCP tool read_document.